Enhancing Therapeutic Response and Overcoming Resistance to Checkpoint Inhibitors in Ovarian Cancer through Cell Cycle Regulation
Open Access
- 17 September 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (18) , 10018
Abstract
Tumor cells invade normal surrounding tissues through continuous division. In this study, we hypothesized that cell cycle regulation changes the immune efficacy of ovarian cancer. To investigate this hypothesis, a Förster resonance energy transfer (FRET) sensor was constructed to characterize the cell activity in real time. Cell shrinkage caused by apoptosis induces the aggregation of proteins on the cell membrane, leading to variations in the fluorescence lifetime of FRET sensors. Moreover, we tracked cell activity across various cycles following co-culture with an immune checkpoint inhibitor. Consequently, we assessed how cell cycle regulation influences immunotherapy in a tumor mouse model. This approach, which involves inhibiting typical cell cycle processes, markedly enhances the effectiveness of immunotherapy. Our findings suggest that modulating the cycle progression of cancer cells may represent a promising approach to enhance the immune response of ovarian cancer cells and the efficacy of immunotherapy based on immune checkpoint inhibitors.Keywords
Funding Information
- National Natural Science Foundation of China (62225505, 61935012, 62175163, 61835009, 62127819, 62205220, JCYJ20200109105404067, RCJC20210706091949022, ZDSYS20210623092006020)
- National Key Research and Shenzhen Key Projects (62225505, 61935012, 62175163, 61835009, 62127819, 62205220, JCYJ20200109105404067, RCJC20210706091949022, ZDSYS20210623092006020)
- Shenzhen Talent Innovation Project (62225505, 61935012, 62175163, 61835009, 62127819, 62205220, JCYJ20200109105404067, RCJC20210706091949022, ZDSYS20210623092006020)
- Shenzhen Science and Technology Planning Project (62225505, 61935012, 62175163, 61835009, 62127819, 62205220, JCYJ20200109105404067, RCJC20210706091949022, ZDSYS20210623092006020)
This publication has 30 references indexed in Scilit:
- Targeting cell-cycle machinery in cancerCancer Cell, 2021
- New strategies in ovarian cancer treatmentCancer, 2019
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian CancerJAMA Oncology, 2019
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyThe Lancet Oncology, 2018
- Role of the nucleus in apoptosis: signaling and executionCellular and Molecular Life Sciences, 2015
- Mixed‐polarization phenotype of ascites‐associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapseInternational Journal of Cancer, 2013
- The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?American Journal of Obstetrics and Gynecology, 2008
- Imaging protein molecules using FRET and FLIM microscopyCurrent Opinion in Biotechnology, 2005
- Src family kinases in tumor progression and metastasisCancer and Metastasis Reviews, 2003
- Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptorCell, 1992